Tivumecirnon is an oral C-C chemokine receptor 4 (CCR4) antagonist claimed to improve immune activity within the tumour ...

Raythera Inc. has described C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, systemic lupus erythematosus, ...

Shanghai Pharmaceuticals Holding Co. Ltd. has identified C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, ...

Zelnecirnon is a small molecule C-C motif chemokine receptor 4 (CCR4) agonist. CCR4 is expressed by several immune cells such as T helper 2 (TH2) cells, regulatory T cells (Tregs), mast cells ...

For example, Matsushima’s anti-leukaemia drug, mogamulizumab, targets the chemokine receptor CCR4 expressed on some T cells, including in leukaemia. “Anti-CCR4 antibody can induce remission ...

The authors examined a number of candidate chemokines and showed that CCL22, produced by both macrophages and tumour cells, attracts regulatory T cells, which express the CCL22 receptor CCR4.